Total cancer care moffit cancer center
GO
 

Richard Kim, MD

Where You Are:
Richard Kim, MD

Assistant Member

Office  (813) 745-1277

Education And Training
  • Postdoctoral Fellow, Yale University Comprehensive Cancer Center, 2006 - Hematology and Medical Oncology
  • Resident, University of Illinois, 2003 - Internal Medicine
  • Intern, New York University Downtown Hospital, 2001 - Internal Medicine
  • MD, University of Miami School of Medicine, 2000


Dr. Richard Kim specializes in gastrointestinal oncology. As a clinical investigator, Dr. Kim’s main interest is conducting novel clinical trials. Currently he is a principal investigator in multiple investigator-initiated and pharmaceutical phase I and phase II trials using novel targeted agents in gastrointestinal tumors, especially focusing on hepatobiliary and colon cancer.

  • Kim R, Tan A, Choi M, El-Rayes BF. Geographic differences in approach to advanced gastric cancer: Is there a standard approach?. Crit Rev Oncol Hematol. 2013 Jun. Pubmedid: 23764501.
  • Waghray A, Balci B, El-Gazzaz G, Kim R, Pelley R, Menon KN, Estfan B, Romero-Marrero C, Aucejo F. Safety and efficacy of sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation. Clin Transplant. 2013 Jun. Pubmedid: 23758296.
  • Xie H, Jiang W, Jiang J, Wang Y, Kim R, Liu X, Liu X. Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma. Cancer. 2013 Feb;119(1):173-181. Pubmedid: 22736490.
  • Kothari N, Saif MW, Kim R. First-line treatment for advanced pancreatic cancer. JOP. 2013;14(2):129-132. Pubmedid: 23474553.
  • Kim R, Kubal T. To give or not to give anti-epidermal growth factor receptor (EGFR) monoclonal antibodies to patients with KRAS G13D mutation in advanced colorectal cancer. Clin Colorectal Cancer. 2012 Aug;11(2):85-87. Pubmedid: 22169039.
  • Choi M, Razzaque S, Kim R. A Phase II Trial of Preoperative Concurrent Chemotherapy/Radiation Therapy Plus Bevacizumab/Erlotinib in the Treatment of Localized Esophageal Cancer. Clin Adv Hematol Oncol. 2012 Jul;10(7):442-451. Pubmedid: 22895284.
  • Choi M, Kim R, Saif MW. What options are available for refractory pancreatic cancer?. JOP. 2012 Jul;13(2):163-165. Pubmedid: 22406591.
  • Strosberg JR, Yeatman T, Weber J, Coppola D, Schell MJ, Han G, Almhanna K, Kim R, Valone T, Jump H, Sullivan D. A phase II study of RO4929097 in metastatic colorectal cancer. Eur J Cancer. 2012 May;48(7):997-1003. Pubmedid: 22445247.
  • Estfan B, Byrne M, Kim R. Sorafenib in Advanced Hepatocellular Carcinoma: Hypertension as a Potential Surrogate Marker for Efficacy. Am J Clin Oncol. 2012 Apr. Pubmedid: 22547010.
  • Kim R, Byer J, Saif MW. BRCA and Pancreatic Cancer: Selection of Chemotherapy. JOP. 2012;13(2):180-181. Pubmedid: 22406596.
  • Kim R, Menon N, Aucejo F. Safe use of sorafenib in a patient undergoing salvage liver transplantation for recurrent hepatocellular carcinoma after hepatic resection. Med Oncol. 2011 Dec;28(4):1044-1047. Pubmedid: 20635167.
  • Lance C, McLennan G, Obuchowski N, Cheah G, Levitin A, Sands M, Spain J, Srinivas S, Shrikanthan S, Aucejo FN, Kim R, Menon KV. Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol. 2011 Dec;22(12):1697-1705. Pubmedid: 21983055.
  • Fujiki M, Aucejo F, Kim R. General overview of neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: necessity or option?. Liver Int. 2011 Sep;31(8):1081-1089. Pubmedid: 22008644.
  • Kim R, Tan A, Lai KK, Jiang J, Wang Y, Rybicki LA, Liu X. Prognostic roles of human equilibrative transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) in resected pancreatic cancer. Cancer. 2011 Sep;117(14):3126-3134. Pubmedid: 21264835.
  • Lazaryan A, Kalmadi S, Almhanna K, Pelley R, Kim R. Predictors of clinical outcomes of resected ampullary adenocarcinoma: a single-institution experience. Eur J Surg Oncol. 2011 Sep;37(9):791-797. Pubmedid: 21741199.
  • Liu X, Jiang W, Aucejo F, Kim R, Miller C, Byrne M, Lopez R, Yerian L. Insulin-like growth factor I receptor β expression in hepatocellular carcinoma. Hum Pathol. 2011 Jun;42(6):882-891. Pubmedid: 21292299.
  • Kim R, Byrne MT, Tan A, Aucejo F. What is the indication for sorafenib in hepatocellular carcinoma? A clinical challenge. Oncology (Williston Park). 2011 Mar;25(3):283-91, 295. Pubmedid: 21548473.
  • Kim R, Aucejo F. Radiologic complete response with sirolimus and sorafenib in a hepatocellular carcinoma patient who relapsed after orthotopic liver transplantation. J Gastrointest Cancer. 2011 Mar;42(1):50-53. Pubmedid: 20714941.
  • Kim R. FOLFIRINOX: a new standard treatment for advanced pancreatic cancer?. Lancet Oncol. 2011 Jan;12(1):8-9. Pubmedid: 21050812.
  • Kim R, Tsao R, Tan A, Byrne M, Almhanna K, Lazaryan A, Elson P, Pelley RJ. A single institution review of adjuvant therapy outcomes for resectable pancreatic adenocarcinoma: outcome and prognostic indicators. J Gastrointest Surg. 2010 Jul;14(7):1159-1169. Pubmedid: 20446118.
  • Tan A, Aucejo F, Kim R. Is there a role for adjuvant treatment after hepatic resection for hepatocellular carcinoma?. Oncology. 2010 Jun;78(3-4):161-171. Pubmedid: 20530972.
  • Phillips B, Kalady M, Kim R. BRAF testing in advanced colorectal cancer: is it ready for prime time?. Clin Adv Hematol Oncol. 2010 Jun;8(6):437-444. Pubmedid: 20733556.
  • Kim R. Cetuximab and panitumumab: are they interchangeable?. Lancet Oncol. 2010 Jan;10(12):1140-1141. Pubmedid: 19875336.
  • Kim R, El-Gazzaz G, Tan A, Elson P, Byrne M, Chang YD, Aucejo F. Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation. Oncology. 2010;79(1-2):62-66. Pubmedid: 21071991.
  • Kim R, Tan A, Estfan B, Aucejo F. Adjuvant treatment after orthotopic liver transplantation: is it really necessary?. Oncology (Williston Park). 2009 Dec;23(14):1276-1281. Pubmedid: 20120841.
  • Wesolowski R, Lee C, Kim R. Is there a role for second-line chemotherapy in advanced gastric cancer?. Lancet Oncol. 2009 Sep;10(9):903-912. Pubmedid: 19717092.
  • Anderson C, Kim R. Adjuvant therapy for resected extrahepatic cholangiocarcinoma: a review of the literature and future directions. Cancer Treat Rev. 2009 Jun;35(4):322-327. Pubmedid: 19147294.
  • Aucejo F, Kim R, Zein N, Quintini C, Uso TD, Lopez R, Eghtesad B, Fung J, Miller C, Yerian L. Vascular endothelial growth factor receptor 2 expression in non-tumorous cirrhotic liver is higher when hepatoma is beyond Milan criteria. Liver Transpl. 2009 Feb;15(2):169-176. Pubmedid: 19177438.
  • Saif MW, Hashmi S, Zelterman D, Almhanna K, Kim R. Capecitabine vs continuous infusion 5-FU in neoadjuvant treatment of rectal cancer. A retrospective review. Int J Colorectal Dis. 2009 Jan;23(2):139-145. Pubmedid: 17909820.
  • Almhanna K, Kim R. Second-line therapy for gemcitabine-refractory pancreatic cancer: is there a standard?. Oncology (Williston Park). 2008 Sep;22(10):1176-1183. Pubmedid: 18935928.
  • Saif MW, Kim R. Role of platinum agents in the management of advanced pancreatic cancer. Expert Opin Pharmacother. 2007 Nov;8(16):2719-2727. Pubmedid: 17956194.
  • Almhanna K, Kalmadi S, Pelley R, Kim R. Neoadjuvant therapy for hepatocellular carcinoma: is there an optimal approach?. Oncology (Williston Park). 2007 Aug;21(9):1116-1122. Pubmedid: 17910314.
  • Kim R, Saif MW. Is there an optimal neoadjuvant therapy for locally advanced pancreatic cancer?. JOP. 2007 May;8(3):279-288. Pubmedid: 17495356.
  • Saif MW, Kim R. Incidence and management of cutaneous toxicities associated with cetuximab. Expert Opin Drug Saf. 2007 Mar;6(2):175-182. Pubmedid: 17367263.
  • Kim R, Chabot J, Saif MW. Adjuvant Treatment for Ampullary Cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011. JOP. 2011;12(4):362-363. Pubmedid: 21737897.

Office: (813) 745-1277

BACK TO RESEARCH PAGE
 
TOOLS:   Font Size
 |  Site Map  |  Privacy Policy  |  Terms and Conditions  |  Staff Login